LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Cost POC Analyzers to Be Introduced at Medica 2012

By LabMedica International staff writers
Posted on 07 Nov 2012
The Quo-Lab glycated hemoglobin (HbA1c) analyzer for the management of diabetes, and a new strip-based analyzer, the STAT-Site M bHB for near patient testing of ketosis, will be introduced at Medica 2012, in Dusseldorf (Germany) during November 14-16, 2012. The analyzers are a product of EKF Diagnostics (Cardiff, United Kingdom).

The semi-automated Quo-Lab HbA1c analyzer is CE marked and provides accurate, affordable, and easy-to-use technology for GP surgeries, diabetes clinics, and laboratories. HbA1c monitoring is increasingly used in the detection and management of diabetes and Quo-Lab is designed to meet the needs of resource poor countries where diabetes is increasing. Only 4 µL of venous or finger prick blood is required for the test and results are available within four minutes.

Image: semiautomated Quo-Lab HbA1c analyzer (Photo courtesy of EKF Diagnostics).
Image: semiautomated Quo-Lab HbA1c analyzer (Photo courtesy of EKF Diagnostics).

EKF's first strip-based ketone analyzer, the Stat-Site M bHB promises to take testing for ketoacidosis out of the laboratory and into the emergency room. Beta-Hydroxybutyrate (bHB) is the main ketone produced during ketosis and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis.

The launch of STAT Site M bHB follows the recent release of the b-Hydroxybutyrate (bHB) LiquiColor Reagent System developed by the EKF subsidiary, Stanbio Laboratory.

Related Links:

EKF Diagnostics



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Latest Hematology News

New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy

WBC Count Could Predict Severity of COVID-19 Symptoms



Sekisui Diagnostics UK Ltd.